Brief: Hansa Biopharma AB Says Imlifidase Met Primary Endpoint In 16-Hmedides-12 Phase 2 Trial
14/12/2023 19:03
Dec 14 (Reuters) - Hansa Biopharma AB HNSA.ST :
* IMLIFIDASE MET PRIMARY ENDPOINT IN 16-HMEDIDES-12 PHASE 2
TRIAL
IN PATIENTS WITH AMR FOLLOWING KIDNEY TRANSPLANTATION
* STATISTICALLY SIGNIFICANT REDUCTION IN DONOR-SPECIFIC
ANTIBODIES
(DSAS) OBSERVED AMONG IMLIFIDASE PATIENTS WITHIN FIVE DAYS OF
TREATMENT
* IMLIFIDASE DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH
PREVIOUS CLINICAL TRIALS
Source text for Eikon: ID:nWkr8m8Jvn
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS